相似文献
1
Primate testing of TGN1412: right target, wrong cell.
Br J Pharmacol. 2010 Oct;161(3):509-11. doi: 10.1111/j.1476-5381.2010.00925.x.
2
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
Br J Pharmacol. 2010 Oct;161(3):512-26. doi: 10.1111/j.1476-5381.2010.00922.x.
3
After TGN1412: recent developments in cytokine release assays.
J Immunotoxicol. 2013 Jan-Mar;10(1):75-82. doi: 10.3109/1547691X.2012.711783. Epub 2012 Sep 11.
4
Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28.
MAbs. 2014 May-Jun;6(3):697-707. doi: 10.4161/mabs.28375. Epub 2014 Mar 5.
5
"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
J Immunol. 2007 Sep 1;179(5):3325-31. doi: 10.4049/jimmunol.179.5.3325.
6
Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
Toxicol Appl Pharmacol. 2019 Jun 1;372:57-69. doi: 10.1016/j.taap.2019.03.020. Epub 2019 Mar 23.
7
CD28 superagonists: what makes the difference in humans?
Immunity. 2008 May;28(5):591-5. doi: 10.1016/j.immuni.2008.04.003.
8
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
Blood. 2011 Dec 22;118(26):6772-82. doi: 10.1182/blood-2010-12-319780. Epub 2011 Sep 19.
9
Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies.
PLoS One. 2008 Mar 5;3(3):e1708. doi: 10.1371/journal.pone.0001708.
10
Antibody C region influences TGN1412-like functional activity in vitro.
J Immunol. 2012 Dec 15;189(12):5831-40. doi: 10.4049/jimmunol.1201795. Epub 2012 Nov 12.
引用本文的文献
1
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Blood. 2024 May 23;143(21):2152-2165. doi: 10.1182/blood.2023023381.
2
Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties.
MAbs. 2023 Jan-Dec;15(1):2220839. doi: 10.1080/19420862.2023.2220839.
3
The 'cytokine storm': molecular mechanisms and therapeutic prospects.
Trends Immunol. 2021 Aug;42(8):681-705. doi: 10.1016/j.it.2021.06.001. Epub 2021 Jul 1.
4
Immune Checkpoints as Therapeutic Targets in Autoimmunity.
Front Immunol. 2018 Oct 8;9:2306. doi: 10.3389/fimmu.2018.02306. eCollection 2018.
5
Advanced model systems and tools for basic and translational human immunology.
Genome Med. 2018 Sep 28;10(1):73. doi: 10.1186/s13073-018-0584-8.
6
Revisiting CD28 Superagonist TGN1412 as Potential Therapeutic for Pediatric B Cell Leukemia: A Review.
Diseases. 2018 May 19;6(2):41. doi: 10.3390/diseases6020041.
7
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.
Immunol Rev. 2017 Mar;276(1):192-212. doi: 10.1111/imr.12523.
8
Early implementation of QbD in biopharmaceutical development: a practical example.
Biomed Res Int. 2015;2015:605427. doi: 10.1155/2015/605427. Epub 2015 May 17.
9
Anti-CD28 Antibody-Initiated Cytokine Storm in Canines.
Transplant Direct. 2015 Mar;1(2). doi: 10.1097/TXD.0000000000000516.
10
The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.
Curr Pain Headache Rep. 2015;19(2):2. doi: 10.1007/s11916-014-0472-x.
本文引用的文献
1
Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.
Br J Clin Pharmacol. 2018 Jul;84(7):1401-1409. doi: 10.1111/bcp.13550. Epub 2018 May 30.
2
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
Br J Pharmacol. 2010 Oct;161(3):512-26. doi: 10.1111/j.1476-5381.2010.00922.x.
3
Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice.
PLoS One. 2009;4(2):e4643. doi: 10.1371/journal.pone.0004643. Epub 2009 Feb 27.
4
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies.
Adv Immunol. 2007;95:111-48. doi: 10.1016/S0065-2776(07)95004-X.
5
Lessons from TGN1412.
Lancet. 2006 Nov 4;368(9547):1569-70; author reply 1570. doi: 10.1016/S0140-6736(06)69651-7.
6
Establishing risk of human experimentation with drugs: lessons from TGN1412.
Lancet. 2006 Oct 14;368(9544):1387-91. doi: 10.1016/S0140-6736(06)69562-7.
7
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
N Engl J Med. 2006 Sep 7;355(10):1018-28. doi: 10.1056/NEJMoa063842. Epub 2006 Aug 14.
8
Development and homeostasis of T cell memory in rhesus macaque.
J Immunol. 2002 Jan 1;168(1):29-43. doi: 10.4049/jimmunol.168.1.29.
Zotero 插件